Novartis1d
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.
Natural Cures on MSN2d
#1 Vitamin to Stop Proteinuria and Repair Kidneys
Clemson University baseball head coach Erik Bakich shares the mentality behind his team's decision to shake hands with ...
Novartis Pharma AG: Novartis oral Fabhalta (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...
BioWorld4d
Biocity’s SC-0062 hits phase II endpoints in diabetic kidney disease
Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II diabetic kidney disease cohort. Conducted ...
Too Old to Operate5d
Role of Iptacopan in Reducing Proteinuria in IgA Nephropathy
The following is a summary of “Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy,” published in the ...
FierceBiotech5d
BioCity's ETA antagonist reduces proteinuria in phase 2 trial of diabetic kidney disease
BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of ...